Research Participants' High Expectations of Benefit in Early-Phase Oncology Trials: Are We Asking the Right Question?
- 10 December 2012
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (35), 4396-4400
- https://doi.org/10.1200/jco.2011.40.6587
Abstract
Purpose: To determine whether patients' expectations of benefit in early-phase oncology trials depend on how patients are queried and to explore whether expectations are associated with patient characteristics. Patients and Methods: Participants were 171 patients in phase I or II oncology trials in the United States. After providing informed consent for a trial but before receiving the investigational therapy, participants answered questions about expectations of benefit. We randomly assigned participants to one of three groups corresponding to three queries about expectations: frequency type, belief type, or both. Main outcomes were differences in expectations by question type and the extent to which expectations were associated with demographic characteristics, numeracy, dispositional optimism, religiousness/spirituality, understanding of research, and other measures. Results: The belief-type group had a higher mean expectation of benefit (64.4 of 100) than the combination group (51.6; P = .01) and the frequency-type group (43.1; P < .001). Mean expectations in the combination and frequency groups were not significantly different (P = .06). Belief-type expectations were associated with a preference for nonquantitative information (r = −0.19; 95% CI, −0.19 to −0.36), knowledge about research (r = −0.21; 95% CI, −0.38 to −0.03), dispositional optimism (r = 0.20; 95% CI, 0.01 to 0.37), and spirituality (r = 0.22; 95% CI, 0.03 to 0.38). Frequency-type expectations were associated with knowledge about clinical research (r = −0.27; 95% CI, −0.27 to −0.51). Conclusion: In early-phase oncology trials, patients' reported expectations of benefit differed according to how patients were queried and were associated with patient characteristics. These findings have implications for how informed consent is obtained and assessed.Keywords
This publication has 29 references indexed in Scilit:
- The culture of faith and hopeCancer, 2010
- Benefit in phase 1 oncology trials: therapeutic misconception or reasonable treatment option?Clinical Trials, 2008
- Varieties of uncertainty and the validity of informed consentClinical Trials, 2008
- Expectations of Benefit in Early-Phase Clinical Trials: Implications for Assessing the Adequacy of Informed ConsentMedical Decision Making, 2008
- Validation of the Subjective Numeracy Scale: Effects of Low Numeracy on Comprehension of Risk Communications and Utility ElicitationsMedical Decision Making, 2007
- Therapeutic misconception in early phase gene transfer trialsSocial Science & Medicine, 2006
- Risks and Benefits of Phase 1 Oncology Trials, 1991 through 2002New England Journal of Medicine, 2005
- Understanding of an aggregate probability statement by patients who are offered participation in Phase I clinical trialsCancer, 2004
- Perceptions of Patients and Physicians Regarding Phase I Cancer Clinical Trials: Implications for Physician-Patient CommunicationJournal of Clinical Oncology, 2003
- The Framing of Decisions and the Psychology of ChoiceScience, 1981